{"id":"W3111161573","doi":"10.1002/onco.13628","title":"A Randomized Phase II Study of AGS-16C3F Versus Axitinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; University of British Columbia","funders":"Astellas Pharma","keywords":"Axitinib; Medicine; Renal cell carcinoma; Clinical endpoint; Internal medicine; Adverse effect; Population; Oncology; Phases of clinical research; Nausea; Gastroenterology; Urology; Pharmacology; Randomized controlled trial; Clinical trial; Sunitinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004781662,0.0002922679,0.001257682,0.00008483262,0.00008217178,0.000009606789,0.0001913696,0.00004456148,0.00009832968],"category_scores_gemma":[0.0002781537,0.0001504036,0.0001513155,0.0004299999,0.0002792704,0.00003972429,0.00009777434,0.0002348737,0.00001303422],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002257999,"about_ca_system_score_gemma":0.0001745837,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008955061,"about_ca_topic_score_gemma":0.0002031721,"domain_scores_codex":[0.997507,0.0007193746,0.0006426442,0.0003719818,0.0004508945,0.0003081281],"domain_scores_gemma":[0.9982857,0.000616958,0.0003779808,0.000415284,0.0001338485,0.0001701916],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9402438,0.01673212,0.0265891,0.0001380262,0.0006099156,0.0009437188,0.01223021,0.0001049951,0.0005053818,0.000007919821,0.0002839728,0.001610795],"study_design_scores_gemma":[0.894092,0.08115951,0.01703067,0.00004109161,0.002519032,0.000005652544,0.001874359,0.0002407399,0.002817566,0.000003897657,0.00005195761,0.0001635619],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9901128,0.0002454163,0.000006347973,0.0004334597,0.00003858366,0.005866497,0.00001726024,0.00003813582,0.003241498],"genre_scores_gemma":[0.9990435,0.000009067845,0.0001855556,0.0001172753,0.00003249392,0.0003482543,0.00006912249,0.00002961704,0.0001650807],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06442739,"threshold_uncertainty_score":0.6133283,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0631375381713145,"score_gpt":0.3153081944287101,"score_spread":0.2521706562573955,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}